Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.
Filter by year:All 2021 2020 2019 2018 2017 2016 2015 2014 2012 2011 2010 2009 2008 2007 2006 2005 2001 2000 1998 1997 1996 1995 1994 1993 1992 1991 1990 1988 1986 1985
Al-Hilaly, Y.K. et al. (2018) Cysteine-independent inhibition of Alzheimer’s disease-like paired helical filament assembly by leuco-methylthioninium (LMT) J. Molec. Biol., Available at: Journal of Molecular Biology
Frahm, S, et al. (2018) Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease. Available at: Behavioural Brain Research.
König, M., et al (2018) Increased cholinergic response in α-synuclein transgenic mice (h-α-synL62). Available at: ACS Chemical Neuroscience
Schwab, K, et al. (2018) A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy. Available at: Frontiers in Molecular Neuroscience
Wilcock, G.K., et al (2018) Correspondence: Letter by Howard and Berry and Response by Wilcock et al. Is LMTM the Norwegian Blue of Alzheimer's Therapy? Available at: Journal of Alzheimer's Disease.